微創醫療(00853.HK)擬6.5億元收購上海浦東物業 將用作新興業務的研發、生產和辦公用途
格隆匯10月5日丨微創醫療(00853.HK)宣佈,公司附屬公司上海微創投資控股有限公司("微創投資")與上海華博信息服務有限公司和上海奉竣企業管理合夥企業(有限合夥)("轉讓人")於近日簽署增資及股權轉讓協議,據此,微創投資將向轉讓人收購上海寰博數碼科技有限公司("目標公司")100%的股權,交易代價約為人民幣6.5億元,惟須根據目標公司於交割日的淨資產值而調整。
據悉,目標公司的主要資產為位於上海浦東新區古丹路18號1-12幢的物業("目標物業")。待此次收購完成後,集團將擁有目標物業。目標物業毗鄰國家級上海生物醫藥科技產業基地-張江生物醫藥基地。目標物業的佔地面積約31,714平方米,物業總建築面積約69,169.7平方米。於交易完成後,目標物業將作為集團近期收購的公司,福建科瑞藥業有限公司的研發基地之一,同時也將用作集團新興業務(如生物新材料、再生醫學等)的研發、生產和辦公用途,為多個特定業務條線部分緩解研發與生產場地緊缺的局面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.